Angiotensin II Receptor Blockade Expert Column

 
 
  • Angiotensin Receptor Blockers: Benefits Beyond Blood Pressure Lowering? VALIDD has just published, and ONTARGET and NAVIGATOR are much anticipated -- and now a leading investigator discusses whether ARBs have special therapeutic qualities beyond blood pressure lowering.
  • Raised Blood Pressure and Hypertension The first measurement almost every clinician takes from a patient is the "blood pressure"; but lately what that is and what to do with it needs to be rethought.
  • Diastolic Heart Failure and RAAS Inhibition A reduced EF is the diagnostic criterion of heart failure, but many patients present with preserved EF -- and yet they may or may not have HF. What is the diagnosis -- and what is the treatment?
  • The Val-MARC Trial and the Role of C-Reactive Protein (CRP) Given the angiotensin receptor blockers (ARBs) mixed record in hypertension, Val-MARC was designed to assess their effect on a cardiovascular disease risk marker -- C-reactive protein.
  • An Expert Interview With Thomas D. Giles, MD The intellectual definition of "hypertension" is evolving -- but how should this impact how the clinician approaches the patient with elevated blood pressure levels?
  • Hypertension in the Elderly Why is blood pressure control in the elderly so poor, and what are the best treatments for hypertension in the elderly?
  • Angiotensin Receptor Blockers: What Is Their Current Status? In an informal survey of some 800 physicians, what antihypertensive drug did over 90% say they would choose if their own blood pressure needed lowering?
  • Cardiovascular Disease in Patients With Chronic Kidney Disease How does one explain the increased risk for cardiovascular disease in patients with chronic kidney disease? Do they have more classic risk factors or can it be explained by novel risk factors?
  • An Expert Interview With Howard S. Weintraub, MD, FACC Our understanding of what constitutes cardiovascular risk is growing rapidly, and the current rubric is "the cardiovascular continuum" -- but what is it?
  • A Brief Overview of Inhibition of the Renin-Angiotensin System The authors review the molecular mechanisms of the renin-angiotensin-aldosterone system (RAAS) and relate them to the potential role and benefits of angiotensin II receptor blockers (ARBs).
  • Hypertension -- Unique Phenotypes and Antihypertensive Treatment New trials, new evidence-based medicine, new guidelines -- how should all this new information be interpreted?
  • Clinical Implications of VALUE The VALUE trial results reinforced the message that hypertension must be treated -- but what about the frequent comorbidity, diabetes?
  • VALIANT: Further Considerations and Clinical Implications Post-MI patients with LV dysfunction and signs of heart failure are at the highest risk -- so it can only be good news if a new drug therapy class proves to be equivalent to the current gold standard.